SABS (SAB Biotherapeutics) Forward P/E Multiple
SAB Biotherapeutics (SABS) is currently undergoing the clinical validation stage of an innovative method for combating type 1 diabetes. The trend of the company's forward P/E ratio clearly demonstrates market expectations, where the 0.00 level indicates the status of the parameter. The business is creating a defensive barrier by utilizing polyclonal antibodies from transgenic livestock. The DiversitAb platform enables the rapid production of proteins against cancer and viruses, ensuring strategic security.
Analytical breakdowns for SAB Biotherapeutics
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
Total Debt to Equity Ratio SAB Biotherapeutics|SABS - Long-Term Debt to Capital|Short-Term Debt to Equity SAB Biotherapeutics|SABS - Company Aggregate Debt|Debts to Book Capitalization SAB Biotherapeutics Inc.|SABS - Long-Term Debt|Company Short-Term Debt SAB Biotherapeutics|Quick Ratio sabbiotherapeutics.com
- company profitability and valuation multiples indicators:
SABS - Net Profit|Projected Future Earnings SAB Biotherapeutics|SABS - Price to Earnings Ratio|Projected Price to Earnings SAB Biotherapeutics, Inc|SABS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple SAB Biotherapeutics Inc.|SABS - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) SAB Biotherapeutics|SABS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months sabbiotherapeutics.com|SABS - Earnings per share growth rate in current year|Expected earnings per share growth for next year SAB Biotherapeutics
Summary company analytics:SAB Biotherapeutics, Inc.
High development costs for the antibody platform and SAB Biotherapeutics (SABS) dependence on external capital make profit forecasts a critical valuation factor. By analyzing the company's expected P/E valuation, an investor determines the cost of one dollar of future net income, which allows for the identification of asset overheating or hidden risks that directly impact long-term capital sustainability.
Competitors of SAB Biotherapeutics (SABS)
Projected Price to Earnings ARGX (argenx)|BNTX (BioNTech Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (abivax.com)|Market Cap to Projected Earnings ADMA Corp (ADMA)|PTGX - Future Price to Earnings|immunovant.com (IMVT) - Projected Price to Earnings|Kiniksa (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols SA|Projected Price to Earnings ADPT|Forward P/E Multiple Celldex Corp|Future Price to Earnings Aurinia Pharmaceuticals (AUPH)|biocryst.com - Price to Future Earnings Ratio|Forward P/E Multiple VERA (Vera Therapeutics)|Dianthus Therapeutics Inc (DNTH) - Projected Price to Earnings Ratio|PHVS - Future Price to Earnings|Market Cap to Projected Earnings AbCellera Biologics ABCL|TRML: Forward P/E Multiple|precigen.com (PGEN) - Forward P/E Multiple|PHAR (Pharming Group) - Forward P/E Multiple|Future Price to Earnings NKTR|Projected Price to Earnings UPB (Upstream Bio Corp)|ZBIO (Zenas Corp) - Future Price to Earnings Multiple|Forward P/E Multiple IMNM (Immunome, Inc.)|gossamerbio.com - Future Price to Earnings|KalVista Pharmaceuticals, Inc. - Forward P/E Multiple|Market Cap to Projected Earnings Septerna, Inc. SEPN|Pieris Pharmaceuticals Inc (PVLA) - Future Price to Earnings|Projected Price to Earnings Ratio Savara Pharma (SVRA)|Projected Price to Earnings RIGL|ANAB (anaptysbio.com) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ATXS|ENGN (enGene Holdings Inc) - Future Price to Earnings Multiple|Forward P/E Multiple RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Projected Price to Earnings Ratio|ACRS - Future Price to Earnings|Future Price to Earnings Multiple KYTX (kyvernatx.com)|TLSA: Forward P/E Multiple|Cabaletta Bio Inc. (CABA) - Forward P/E Multiple|Future Price to Earnings Ventyx Bio|Theratechnologies, Inc - Price to Expected Earnings Ratio|Forward P/E Multiple AVTX|ELDN - Projected Price to Earnings Ratio|Agenus Inc. - Projected Price to Earnings|Forward P/E Multiple Climb Bio Inc. CLYM|ZURA: Projected Price to Earnings|aTyr Pharmaceuticals - Market Cap to Future Earnings Ratio|ADAG: Forward P/E Multiple|IMA - Market Cap to Projected Earnings|STTK (Shattuck Labs Inc) - Forward P/E Multiple|Projected Price to Earnings Equillium Bio (EQ)|Future Price to Earnings Connect Biopharma (CNTB)|Market Cap to Projected Earnings immunic-therapeutics.com|Future Price to Earnings Atara Bio ATRA|Market Cap to Projected Earnings InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. - Forward P/E Multiple|ACET - Forward P/E Multiple|CELU: Forward P/E Multiple|INMB (INmune Bio Corporation) - Future Price to Earnings|Future Price to Earnings Barinthus Biotherapeutics|kezarlifesciences.com (KZR) - Market Cap to Projected Earnings|Future Price to Earnings Akari Therapeutics Plc (AKTX)|ENLV: Price to Expected Earnings Ratio|Forward P/E Multiple QTTB (Q32 Bio)|Future Price to Earnings Multiple GOVX|Edesa Biotech, Inc. - Forward P/E Multiple|IBIO - Forward P/E Multiple|carismatx.com (CARM) - Future Price to Earnings|XTL Biopharmaceuticals Ltd - Future Price to Earnings Multiple|Future Price to Earnings Bolt Biotherapeutics Inc.|Projected Price to Earnings HCW Biologics Inc (HCWB)|Forward P/E Multiple APVO|Forward P/E Multiple AIM ImmunoTech, Inc. (AIM)|Aditxt, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple GRI|XORTX - Forward P/E Multiple|Market Cap to Projected Earnings Vyome Therapeutics HIND|Revelation Biosciences (REVB) - Future Price to Earnings|Projected Price to Earnings indaptusrx.com|Future Price to Earnings Scinai Immunotherapeutics Ltd.|Projected Price to Earnings CalciMedica Corp (CALI)|Projected Price to Earnings AFMD (Affimed)|Forward P/E Multiple allakos.com (ALLK)|Future Price to Earnings HOOKIPA Pharma HOOK|IGMS: Price to Future Earnings Ratio|iTeos Therapeutics, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Ocean Biomedical Inc|TC BioPharm (Holdings) PLC (TCBP) - Future Price to Earnings|THRD - Market Cap to Projected Earnings
